Background. The prevalence of bloodstream infections (BSIs) due to ESBL-producing Escherichia coli (ESBL-EC) strains has increased dramatically over the past years. Objectives. Characterization of ESBL-EC isolates collected from BSIs with regard to their antimicrobial susceptibility and phylogenetic background. The conjugative transfer of resistance determinants to the E. coli reference strain K12 C600 was also investigated. Material and Methods. A collection of forty-eight ESBL-EC strains recovered from BSIs was subjected to the study. These strains were obtained from the ICU (intensive care unit) of the Medical University Hospital, Wrocław, Poland, during a four-year period (2009)(2010)(2011)(2012). All the isolates were screened for ESBL production by the double disk synergy test (DDST). Transferability of plasmid-mediated resistance genes was performed by the conjugational broth method. Susceptibility to antibiotics and chemotherapeutics of clinical isolates and transconjugants was determined by the agar dilution method. PCR assay was used to detect the bla CTX-M gene in ESBL-EC tested and transconjugants. Affiliation to phylogenetic groups was done by the triplex PCR method. Results. Conjugational transfer of plasmids responsible for ESBL to a recipient strain was successful for all the ESBL-EC analyzed (donors). The conjugation frequencies ranging from 2.3 × 10 -7 to 5.2 × 10 -1 per donor. In vitro susceptibility testing revealed that all the ESBL-EC isolates and their transconjugants were resistant to most of the antimicrobial agents tested with the exception of carbapenems, tigecycline, and β-lactam-clavulanate combinations. Moreover, all the donor strains and their transconjugants were found to contain the bla CTX-M gene. The majority of the isolates analyzed belonged to phylogroups B2 (62.5%) and D (25%), whereas groups B1 and A were less frequently represented (8.3% and 4.2%, respectively). Conclusions. The results of the study confirm the need of antibiotic policies and effective infection control measures in hospital settings to minimize BSIs caused by multi-resistant ESBL-producing pathogens (Adv Clin Exp Med 2014, 23, 6, 865-870).
Plasmid-encoded extended-spectrum β-lactama ses (ESBLs) are considered one of the most common mechanisms of resistance to β-lactam antibiotics in Gram-negative rods. Since the first description at the beginning of the 1980s, the number of ESBL types identified has been constantly growing. Currently, more than 700 distinct ESBL variants have been described worldwide. These enzymes are usually classified based on their molecular and biochemical properties as well as substrate preferences [1] . ESBLs constitute the major source of resistance to almost all penicillins, third-generation cephalosporins (3GC) and aztreonam with the exception of cephamycins and carbapenems. Moreover, their hydrolyzing activity is effectively blocked by β-lactamase inhibitors, such as clavulanate, sulbactam or tazobactam [2] . ESBLs are most commonly detected in a wide variety of enterobacterial species, predominantly in Escherichia coli and Klebsiella pneumoniae isolates responsible for community-and hospital-acquired infections. As the authors reported previously, ESBL-expressing enterobacteria usually exhibit co-resistance to a wide range of non-β-lactam antibiotics and chemotherapeutics, including aminoglycosides, trimethoprim-sulfamethoxazole, tetracycline and chloramphenicol [3, 4] . This reduces significantly the number of antimicrobials to which the infecting microorganism is susceptible. Thus, treatment of severe infections caused by multiresistant Enterobacteriaceae expressing ESBLs is often limited to carbapenems [5] . ESBL-producing Escherichia coli (ESBL-EC) is considered the causative agent of many severe and life-threading infections, such as meningitis and bloodstream infections (BSIs). The prevalence of BSIs caused by ESBL-EC has increased dramatically over the past few years [6] [7] [8] . Moreover, hospital-acquired BSIs are frequently associated with many adverse outcomes, including increased rates of treatment failure, prolonged hospital stays, increased morbidity and mortality, and higher economic costs [9, 10] . This study was designed to characterize ESBL-EC clinical isolates collected from BSIs. The primary objectives of the study were to investigate: 1) the conjugative transfer of resistance determinants, 2) the antimicrobial susceptibility patterns, and 3) the phylogenetic group affiliation.
Material and Methods

Bacterial Strains
Between January 2009 and December 2012, a total of 48 non-duplicated ESBL-EC strains were isolated from blood samples from 32 women and 16 men (mean age 59.2 years) from the ICU of the Medical University Hospital, Wrocław, Poland. Identification to species level was carried out using the ATB ID32GN test (bioMérieux) according to the recommendations of the manufacturer.
Phenotypic ESBL Detection and Antimicrobial Susceptibility Testing
The ESBL status of each isolate tested was confirmed by standard double disk synergy test (DDST) using ceftazidime, cefotaxime, cefepime and amoxicillin/clavulanate disks [11] . Klebsiella pneumoniae ATCC 700603 was included as an ES-BL-positive control. The minimal inhibitory concentrations (MICs) of selected antimicrobial agents were determined by the dilution method on Mueller-Hinton agar (bioMérieux) in accordance with the Clinical Laboratory Standards Institute (CLSI) guidelines [12] . MICs of the oxyimino-β-lactams, namely aztreonam, ceftriaxone, ceftazidime and cefotaxime, were also determined in the presence of clavulanate (2 mg/L). Control strains, including E. coli ATCC 25922 and E. coli ATCC 35218, were included in each susceptibility test. The antibiotics and chemotherapeutics tested were provided as follows: cefotaxime, gentamicin, amikacin, clavulanate lithium (Sigma Chemical Co., St Louis, MO, USA), aztreonam (Bristol-Myers Squibb, New Brunswick, NJ, USA), ceftriaxone (Roche, Basel, Switzerland), ceftazidime (Glaxo Wellcome, Stevenage, UK), meropenem (Zeneca, Macclesfield, UK), imipenem (Merck Sharp & Dohme Research), chloramphenicol, co-trimoxazole, tetracycline (Polfa, Tarchomin, Poland), and tigecycline (Wyeth).
Transferability of Plasmid-Mediated ESBLs
Conjugation experiments were carried out between ESBL-EC clinical isolates (donors) and E. coli K12 C600 (recipient), as described previously [4] . Transconjugants were selected on MacConkey agar plates containing nalidixic acid (64 mg/L) and cefotaxime (4 mg/L). Nalidixic acid inhibited the growth of the donors but did not affect that of the recipient. On the other hand, cefotaxime allowed the growth of the donors but inhibited that of the recipient. The combination of these two antimicrobials permitted the growth of the transconjugants. Conjugation frequencies were expressed as the number of transconjugants per donor.
Plasmid DNA Isolation and PCR Assay
Plasmid DNA was isolated from ESBL-EC donor strains and transconjugants using the Plasmid Mini Kit (Qiagen, Germany) in accordance with the manufacturer's methodology. The prepared plasmids were subjected to PCR for the presence of the bla CTX-M gene in donors and their transconjugants. The primer pairs and PCR conditions were as described previously [4] .
Determination of Phylogenetic Groups
Affiliation of the ESBL-EC strains studied to phylogenetic groups (A, B1, B2, D) was done using the triplex PCR method initially developed by Clermont et al. [13] . This method applied primers targeting genes: chuA, yjaA, and a noncoding region, TSPE4.C2. The PCR assay consisted of initial 
Results and Discussion
Conjugation Experiments
All of the 48 E. coli bloodstream isolates tested were found to express ESBL phenotype based on the positive results of the DDST. Overall, a total of 48 conjugation crossings between ESBL-EC clinical isolates (donors) and E. coli strain K12 C600 (recipient) were carried out. As shown in Table 1 The transconjugants obtained in transferability assays were positive for ESBL production according to conventional DDST. The current study showed an extremely effective mechanism of ESBL dissemination in Gram-negative bacilli by means of conjugation is consistent with our previous observations [3, 4] . Table 2 summarizes the results of in vitro susceptibilities obtained for ESBL-EC clinical isolates (donors) and their transconjugants. Generally, the susceptibility of donor strains reflected well antibiotic-resistance patterns specific to ESBL-producing microorganisms. All of the ESBL-EC isolates were highly resistant to aztreonam, cefotaxime and ceftriaxone. On the other hand, 12 out of the 48 isolates were susceptible to ceftazidime. The MICs of third-generation cephalosporins and aztreonam were strongly reduced in the presence of β-lactamase inhibitor (clavulanate) at a fixed concentration of 2 mg/L. Additionally, ESBL-EC isolates remained susceptible to the carbapenems tested (meropenem and imipenem). These findings confirm that carbapenems are first line therapy in patients infected with ESBL-producing bacteria and are in agreement with previous reports [5, 14] . Apart from β-lactam drugs, the ESBL-EC isolates studied were uniformly resistant to co-trimoxazole and most of them (42/48) also displayed resistance to amikacin and gentamicin. Moreover, resistance to tetracycline and chloramphenicol was demonstrated in 18 and 6 strains, respectively. However, none of the ESBL-EC isolates was resistant to tigecycline. Our results demonstrate that tigecycline appears to be efficacious against multidrug resistant pathogens, including ESBL-producing organisms, and are consistent with data of previous studies [15, 16] . Almost all transconjugants obtained in the mating experiments showed similar antibiotic resistance profile as donor strains ( Table 2 ). All of them were resistant to aztreonam, cefotaxime, and ceftriaxone, but susceptible to meropenem, imipenem and oxyimino-β-lactam-clavulanate combinations. Ceftazidime resistance was observed in 12 (25%) transconjugants. The data concerning the susceptibility to non-β-lactam antibiotics showed that 36 (75%) out of the 48 transconjugants showed resistance to co-trimoxazole and gentamicin. In addition, 35 (72.9%) of them were resistant to amikacin. Moreover, resistance to chloramphenicol and tetracycline was demonstrated in one transconjugant only, whereas all the transconjugants were uniformly susceptible to tigecycline. The results of the present study indicate that transferability of ESBL-mediated resistance to oxyimino-β-lactams is directly associated with the resistance to non-β-lactam antibacterial drugs. On the other hand, further studies should be carried out to demonstrate the genetic location of antibiotic resistance markers in the same ESBL-encoding plasmids. 
Susceptibility Testing
PCR-Based Amplification of the bla CTX-M
Cefotaximases (CTX-M-ases) constitute the predominant family among globally distributed ESBLs. These enzymes are not closely related to others families of ESBLs (TEM and SHV), but share a high level of identity with chromosomal β-lactamases derived from Kluyvera spp. [17] . CTX-M-type ESBLs confer higher levels of resistance to cefotaxime than to ceftazidime. The analysis of susceptibility patterns obtained for the ESBL-EC strains tested and their transconjugants revealed that MICs of cefotaxime were significantly higher than those of ceftazidime. Thus, these results may suggest the synthesis of ESBLs belonging to the CTX-M family. PCR-based assays revealed the presence of the bla CTX-M gene in all ESBL-EC clinical isolates as well as their transconjugants. These findings demonstrate the predominance of CTX-M enzymes among ESBL producers and correlate well with our previous observations [4] as well as with data reported by other researchers [18, 19] .
Phylogenetic Group Distribution Among ESBL-EC
Phylogenetic analyses, based on the combination of 3 DNA markers (chuA, yjaA, and TSPE4. C2) have classified E. coli strains into 4 main phylogroups, namely A, B1, B2 and D. It is noteworthy that the phylogenetic group affiliation of E. coli strains is closely associated with their pathogenic potential. Generally, commensal isolates belong mainly to A and B1 groups whereas pathogenic E. coli strains responsible for extraintestinal infections, particularly in hospital settings, are essentially link to the B2 and D phylogroups [13, 20] . The present study showed that the majority of ESBL-EC isolates belonged to phylogroups B2 (62.5%) and D (25%), whereas phylogenetic groups B1 and A were less frequently represented (8.3% and 4.2%, respectively). These findings are generally consistent with those obtained by Sannes et al. [21] and Bukh et al. [22] , who demonstrated that bloodstream E. coli isolates belonged mostly to B2 and D phylogroups.
In conclusion, our study emphasizes the need to apply appropriate infection control measures to reduce severe hospital-acquired infections due to multiresistant ESBL-producing bacteria.
